Search Results | Blood | American Society of Hematology

1-20 of 362

Sort by

Sort Order Select

Journal Articles

Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

Blood (2023) 141 (17): 2047–2061.

DOI: https://doi.org/10.1182/blood.2022018604

Published: 2023

Includes: Supplemental data

Journal Articles

Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1

Blood (2022) 140 (24): 2594–2610.

DOI: https://doi.org/10.1182/blood.2021014241

Published: 2022

Includes: Supplemental data

Journal Articles

Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts

Blood (2022) 140 (20): 2170–2174.

DOI: https://doi.org/10.1182/blood.2022016171

Published: 2022

Includes: Supplemental data

Journal Articles

Gvhd Prophylaxis Incorporating Methotrexate in Allo-HCT for Chronic Myeloid Malignancies and sAML: A Retrospective Analysis from the Cmwp of the EBMT

Blood (2022) 140 (Supplement 1): 900–902.

DOI: https://doi.org/10.1182/blood-2022-160121

Published: 2022

Journal Articles

Clinical Implications of p53 Dysfunction in Patients with Myelodysplastic Syndromes

Blood (2022) 140 (Supplement 1): 4001–4004.

DOI: https://doi.org/10.1182/blood-2022-166050

Published: 2022

Journal Articles

Clinical Outcomes of Myelofibrosis Patients Following Immediate Transition to Momelotinib from Ruxolitinib

Ruben Mesa, Srdan Verstovsek, Uwe Platzbecker, Vikas Gupta, David Lavie, Pilar Giraldo, Jean-Jacques Kiladjian, Stephen T Oh, Timothy Devos, Francesco Passamonti, Miklos Egyed, Alessandro Vannucchi, Andrzej Pluta, Donal P McLornan, Jun Kawashima, Mei Huang, Bryan Strouse, Claire Harrison

Blood (2022) 140 (Supplement 1): 3983–3985.

DOI: https://doi.org/10.1182/blood-2022-159636

Published: 2022

Journal Articles

In Patients with Relapsed/Refractory AML Sequential Conditioning and Immediate Allogeneic Stem Cell Transplantation (allo-HCT) Results in Similar Overall and Leukemia-Free Survival Compared to Intensive Remission Induction Chemotherapy Followed By Allo-HCT: Results from the Randomized Phase III ASAP Trial

Blood (2022) 140 (Supplement 1): 9–11.

DOI: https://doi.org/10.1182/blood-2022-159962

Published: 2022

Journal Articles

Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes

Blood (2022) 140 (Supplement 1): 1121–1124.

DOI: https://doi.org/10.1182/blood-2022-163634

Published: 2022

Journal Articles

Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial

Blood (2022) 140 (Supplement 1): 1109–1111.

DOI: https://doi.org/10.1182/blood-2022-168718

Published: 2022

Journal Articles

Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study

Blood (2022) 140 (Supplement 1): 1106–1108.

DOI: https://doi.org/10.1182/blood-2022-169050

Published: 2022

Journal Articles

Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Blood (2022) 140 (Supplement 1): 145–149.

DOI: https://doi.org/10.1182/blood-2022-158030

Published: 2022

Journal Articles

Rapid Response to Idecabtagene Vicleucel in a Myeloma Patient Refractory to Multiple Prior Lines of Anti-BCMA Directed Therapies

Maximilian Merz, Vladan Vucinic, Song Yau Wang, Christina Kloetzer, Birthe Schetschorke, Jan Sonntag, Jule Ussmann, Saskia Hell, Simone Heyn, Sandra Hoffmann, Enrica Bach, Klaus H. Metzeler, Sebastian Schwind, Marco Herling, Madlen Jentzsch, Georg-Nikolaus Franke, Uwe Platzbecker

Blood (2022) 140 (Supplement 1): 12492–12493.

DOI: https://doi.org/10.1182/blood-2022-164591

Published: 2022

Journal Articles

Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)

Katja Sockel, Sandra Frank, Annika Neu, Markus Ditschkowski, Inken Hilgendorf, Mareen Goeckenjan, Friedrich Stoelzel, Jan Moritz Middeke, Nicolaus Kröger, Francis A. Ayuk, Matthias Eder, Wolfgang Bethge, Jürgen Finke, Hartmut Bertz, Guido Kobbe, Martin Kaufmann, Uwe Platzbecker, David Beverungen, Christoph Schmid, Malte von Bonin, Katharina Egger-Heidrich, Lisa Heberling, Karolin Trautmann-Grill, Raphael Teipel, Gesine Bug, Johanna Tischer, Alessia Fraccaroli, Barbara Holler, Daniel Wolff, Thomas Luft, Wolf Roesler, Kerstin Schäfer-Eckart, Sabine Dressler, Christof Scheid, Udo Holtick, Stefan Klein, Igor Wolfgang Blau, Andreas Burchert, Gerald Wulf, Justin Hasenkamp, Rainer Schwerdtfeger, Stephan Kaun, Christoph Wittke, Friederike Wortmann, Helga Neidlinger, Martin Bornhaeuser, Johannes Schetelig, on Behalf of the German Cooperative Transplant Study Group

Blood (2022) 140 (Supplement 1): 10563–10565.

DOI: https://doi.org/10.1182/blood-2022-162673

Published: 2022

Journal Articles

Multiple Episodes of Transfusion Independence with Luspatercept Treatment and the Impact of Dose Escalation in Patients with Lower-Risk Myelodysplastic Syndromes from the MEDALIST Study

Uwe Platzbecker, Valeria Santini, Rami S. Komrokji, Amer M. Zeidan, Guillermo Garcia-Manero, Rena Buckstein, Esther Natalie Oliva, Veronika Pozharskaya, Xianwei Ha, Jose Alberto Nadal, Dimana Miteva, Pierre Fenaux

Blood (2022) 140 (Supplement 1): 6971–6973.

DOI: https://doi.org/10.1182/blood-2022-157487

Published: 2022

Journal Articles

Quantitative Impact of Mutated NPM1 MRD in Patients with AML Undergoing Allogeneic Stem Cell Transplantation

Sebastian Schwind, Lara Bischof, Marius Bill, Juliane Grimm, Jule Ussmann, Elizabeth Gaston, Donata Backhaus, Dominic Brauer, Marco Herling, Maximilian Merz, Klaus H. Metzeler, Georg-Nikolaus Franke, Vladan Vucinic, Uwe Platzbecker, Madlen Jentzsch

Blood (2022) 140 (Supplement 1): 3412–3413.

DOI: https://doi.org/10.1182/blood-2022-163365

Published: 2022

Journal Articles

Induction of a Systemic Immune Response during Use of an Allogenic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML Patients Correlates with Clinical Response and MRD Conversion

Arjan A. Van de Loosdrecht, Jacqueline Cloos, Eva-Maria Wagner-Drouet, Uwe Platzbecker, Tobias A.W. Holderried, Catharina van Elssen, Aristoteles Giagounidis, Marij J.P. Welters, Sjoerd H. van der Burg, Hester J.T. van Zeeburg, Jeroen Rovers, Bjorn T. Gjertsen

Blood (2022) 140 (Supplement 1): 3410–3411.

DOI: https://doi.org/10.1182/blood-2022-163116

Published: 2022

Journal Articles

Risk Prediction in MDS: A Validation of the IPSS-M and Comparison to IPSS-R and to Two Other Personalized Prediction Tools

Constance Baer, Sandra Huber, Stephan Hutter, Manja Meggendorfer, Niroshan Nadarajah, Wencke Walter, Uwe Platzbecker, Katharina Götze, Wolfgang Kern, Torsten Haferlach, Gregor Hoermann, Claudia Haferlach

Blood (2022) 140 (Supplement 1): 1128–1129.

DOI: https://doi.org/10.1182/blood-2022-159939

Published: 2022

Journal Articles

Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial

Blood (2022) 140 (Supplement 1): 523–525.

DOI: https://doi.org/10.1182/blood-2022-157126

Published: 2022

Journal Articles

Long-Term Outcome of Second Allogeneic Stem Cell Transplantation (HSCT2) for Primary Graft Failure in Patients with Acute Leukemia in Remission: A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Arnon Nagler, Myriam Labopin, Alexander D. Kulagin, Andrea Velardi, Jaime Sanz, Hélène Labussière-Wallet, Victoria Potter, Jurgen Kuball, Simona Sica, Elena N. Parovichnikova, Wolfgang Bethge, Xavier Leleu, Uwe Platzbecker, Friedrich Stölzel, Fabio Ciceri, Mohamad Mohty

Blood (2022) 140 (Supplement 1): 7578–7579.

DOI: https://doi.org/10.1182/blood-2022-156231

Published: 2022

Journal Articles

Collections of Autologous Lymphocytes for Treatment with Chimeric Antigen Receptor (CAR) T-Lymphocytes - No Association of Clonal Hematopoiesis (CH) with Manufacturing Success

Blood (2022) 140 (Supplement 1): 7560–7562.

DOI: https://doi.org/10.1182/blood-2022-163360

Published: 2022

NARROW

Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1

Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts

Gvhd Prophylaxis Incorporating Methotrexate in Allo-HCT for Chronic Myeloid Malignancies and sAML: A Retrospective Analysis from the Cmwp of the EBMT

Clinical Implications of p53 Dysfunction in Patients with Myelodysplastic Syndromes

Clinical Outcomes of Myelofibrosis Patients Following Immediate Transition to Momelotinib from Ruxolitinib

Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes

Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial

Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study

Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Rapid Response to Idecabtagene Vicleucel in a Myeloma Patient Refractory to Multiple Prior Lines of Anti-BCMA Directed Therapies

Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)

Multiple Episodes of Transfusion Independence with Luspatercept Treatment and the Impact of Dose Escalation in Patients with Lower-Risk Myelodysplastic Syndromes from the MEDALIST Study

Quantitative Impact of Mutated NPM1 MRD in Patients with AML Undergoing Allogeneic Stem Cell Transplantation

Induction of a Systemic Immune Response during Use of an Allogenic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML Patients Correlates with Clinical Response and MRD Conversion

Risk Prediction in MDS: A Validation of the IPSS-M and Comparison to IPSS-R and to Two Other Personalized Prediction Tools

Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial

Long-Term Outcome of Second Allogeneic Stem Cell Transplantation (HSCT2) for Primary Graft Failure in Patients with Acute Leukemia in Remission: A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Collections of Autologous Lymphocytes for Treatment with Chimeric Antigen Receptor (CAR) T-Lymphocytes - No Association of Clonal Hematopoiesis (CH) with Manufacturing Success

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only